A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Xevinapant (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms XRAY VISION
- Sponsors EMD Serono Research & Development Institute; Merck KGaA
- 18 Jul 2024 Planned End Date changed from 16 Dec 2030 to 30 Sep 2024.
- 18 Jul 2024 Planned primary completion date changed from 5 Oct 2027 to 30 Sep 2024.
- 18 Jul 2024 Status changed from discontinued to active, no longer recruiting.